{"transactions":[{"id":696860,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":26569,"kind":"person","name":"Kolbeck Roland Wilhelm","position":1,"cik":"0002076327","reported_name":"Kolbeck Roland Wilhelm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-08-04T21:03:20.000Z","date":"2026-08-01","kind":"exercise","planned":false,"acquired":false,"shares":36375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":109125,"derivative":{"underlying":"Common Stock","underlying_shares":36375},"source":{"system":"sec-edgar","filing":"0002076327-26-000006","document":"form4-08042026_090816.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000207632726000006/form4-08042026_090816.xml","form_type":"4"}},{"id":696859,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":26569,"kind":"person","name":"Kolbeck Roland Wilhelm","position":1,"cik":"0002076327","reported_name":"Kolbeck Roland Wilhelm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-04T21:03:20.000Z","date":"2026-08-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":12385,"price":5.2,"value":64402.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":23990,"source":{"system":"sec-edgar","filing":"0002076327-26-000006","document":"form4-08042026_090816.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000207632726000006/form4-08042026_090816.xml","form_type":"4"}},{"id":696858,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":26569,"kind":"person","name":"Kolbeck Roland Wilhelm","position":1,"cik":"0002076327","reported_name":"Kolbeck Roland Wilhelm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-04T21:03:20.000Z","date":"2026-08-01","kind":"exercise","planned":false,"acquired":true,"shares":36375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":36375,"source":{"system":"sec-edgar","filing":"0002076327-26-000006","document":"form4-08042026_090816.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000207632726000006/form4-08042026_090816.xml","form_type":"4"}},{"id":745826,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T20:15:16.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":false,"shares":11580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 5, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 5, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11580},"source":{"system":"sec-edgar","filing":"0001590102-26-000002","document":"form4-06082026_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000159010226000002/form4-06082026_040605.xml","form_type":"4"}},{"id":745825,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T20:15:16.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":10987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":10987,"derivative":{"underlying":"Common Stock","underlying_shares":10987},"source":{"system":"sec-edgar","filing":"0001590102-26-000002","document":"form4-06082026_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000159010226000002/form4-06082026_040605.xml","form_type":"4"}},{"id":745824,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T20:15:16.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":42350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":42350,"derivative":{"exercise_price":4.71,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":42350},"source":{"system":"sec-edgar","filing":"0001590102-26-000002","document":"form4-06082026_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000159010226000002/form4-06082026_040605.xml","form_type":"4"}},{"id":745823,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:15:16.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":true,"shares":11580,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":726403,"source":{"system":"sec-edgar","filing":"0001590102-26-000002","document":"form4-06082026_040605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000159010226000002/form4-06082026_040605.xml","form_type":"4"}},{"id":746196,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40485,"kind":"person","name":"Humphries William D.","position":1,"cik":"0001674278","reported_name":"Humphries William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T20:15:14.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":false,"shares":11580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 5, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 5, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11580},"source":{"system":"sec-edgar","filing":"0001674278-26-000002","document":"form4-06082026_040603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674278/000167427826000002/form4-06082026_040603.xml","form_type":"4"}},{"id":746195,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40485,"kind":"person","name":"Humphries William D.","position":1,"cik":"0001674278","reported_name":"Humphries William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T20:15:14.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":10987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":10987,"derivative":{"underlying":"Common Stock","underlying_shares":10987},"source":{"system":"sec-edgar","filing":"0001674278-26-000002","document":"form4-06082026_040603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674278/000167427826000002/form4-06082026_040603.xml","form_type":"4"}},{"id":746194,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40485,"kind":"person","name":"Humphries William D.","position":1,"cik":"0001674278","reported_name":"Humphries William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T20:15:14.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":42350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":42350,"derivative":{"exercise_price":4.71,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":42350},"source":{"system":"sec-edgar","filing":"0001674278-26-000002","document":"form4-06082026_040603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674278/000167427826000002/form4-06082026_040603.xml","form_type":"4"}},{"id":746193,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40485,"kind":"person","name":"Humphries William D.","position":1,"cik":"0001674278","reported_name":"Humphries William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:15:14.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":true,"shares":11580,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":45105,"source":{"system":"sec-edgar","filing":"0001674278-26-000002","document":"form4-06082026_040603.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674278/000167427826000002/form4-06082026_040603.xml","form_type":"4"}},{"id":745822,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T20:15:14.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":false,"shares":11580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 5, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 5, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11580},"source":{"system":"sec-edgar","filing":"0001654773-26-000003","document":"form4-06082026_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000165477326000003/form4-06082026_040610.xml","form_type":"4"}},{"id":745821,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T20:15:14.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":10987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":10987,"derivative":{"underlying":"Common Stock","underlying_shares":10987},"source":{"system":"sec-edgar","filing":"0001654773-26-000003","document":"form4-06082026_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000165477326000003/form4-06082026_040610.xml","form_type":"4"}},{"id":745820,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T20:15:14.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":42350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":42350,"derivative":{"exercise_price":4.71,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":42350},"source":{"system":"sec-edgar","filing":"0001654773-26-000003","document":"form4-06082026_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000165477326000003/form4-06082026_040610.xml","form_type":"4"}},{"id":745819,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:15:14.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":true,"shares":11580,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":69536,"source":{"system":"sec-edgar","filing":"0001654773-26-000003","document":"form4-06082026_040610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000165477326000003/form4-06082026_040610.xml","form_type":"4"}},{"id":745969,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":391,"kind":"person","name":"MILANO VINCENT","position":1,"cik":"0001187159","reported_name":"MILANO VINCENT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T20:15:12.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":false,"shares":11580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 5, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 5, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11580},"source":{"system":"sec-edgar","filing":"0001187159-26-000002","document":"form4-06082026_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1187159/000118715926000002/form4-06082026_040607.xml","form_type":"4"}},{"id":745968,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":391,"kind":"person","name":"MILANO VINCENT","position":1,"cik":"0001187159","reported_name":"MILANO VINCENT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T20:15:12.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":10987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":10987,"derivative":{"underlying":"Common Stock","underlying_shares":10987},"source":{"system":"sec-edgar","filing":"0001187159-26-000002","document":"form4-06082026_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1187159/000118715926000002/form4-06082026_040607.xml","form_type":"4"}},{"id":745967,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":391,"kind":"person","name":"MILANO VINCENT","position":1,"cik":"0001187159","reported_name":"MILANO VINCENT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T20:15:12.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":42350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":42350,"derivative":{"exercise_price":4.71,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":42350},"source":{"system":"sec-edgar","filing":"0001187159-26-000002","document":"form4-06082026_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1187159/000118715926000002/form4-06082026_040607.xml","form_type":"4"}},{"id":745966,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":391,"kind":"person","name":"MILANO VINCENT","position":1,"cik":"0001187159","reported_name":"MILANO VINCENT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:15:12.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":true,"shares":11580,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":28896,"source":{"system":"sec-edgar","filing":"0001187159-26-000002","document":"form4-06082026_040607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187159/000118715926000002/form4-06082026_040607.xml","form_type":"4"}},{"id":746002,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40436,"kind":"person","name":"GOWEN MAXINE","position":1,"cik":"0001280044","reported_name":"GOWEN MAXINE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T20:15:06.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":false,"shares":11580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 5, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 5, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11580},"source":{"system":"sec-edgar","filing":"0001280044-26-000004","document":"form4-06082026_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280044/000128004426000004/form4-06082026_040601.xml","form_type":"4"}},{"id":746001,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40436,"kind":"person","name":"GOWEN MAXINE","position":1,"cik":"0001280044","reported_name":"GOWEN MAXINE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T20:15:06.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":10987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":10987,"derivative":{"underlying":"Common Stock","underlying_shares":10987},"source":{"system":"sec-edgar","filing":"0001280044-26-000004","document":"form4-06082026_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280044/000128004426000004/form4-06082026_040601.xml","form_type":"4"}},{"id":746000,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40436,"kind":"person","name":"GOWEN MAXINE","position":1,"cik":"0001280044","reported_name":"GOWEN MAXINE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T20:15:06.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":42350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":42350,"derivative":{"exercise_price":4.71,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":42350},"source":{"system":"sec-edgar","filing":"0001280044-26-000004","document":"form4-06082026_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280044/000128004426000004/form4-06082026_040601.xml","form_type":"4"}},{"id":745999,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40436,"kind":"person","name":"GOWEN MAXINE","position":1,"cik":"0001280044","reported_name":"GOWEN MAXINE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:15:06.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":true,"shares":11580,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":33334,"source":{"system":"sec-edgar","filing":"0001280044-26-000004","document":"form4-06082026_040601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280044/000128004426000004/form4-06082026_040601.xml","form_type":"4"}},{"id":746630,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T16:15:16.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":false,"shares":11580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units vested on June 5, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units vested on June 5, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11580},"source":{"system":"sec-edgar","filing":"0001172252-26-000002","document":"form4-06082026_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000117225226000002/form4-06082026_040612.xml","form_type":"4"}},{"id":746629,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T16:15:16.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":10987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":10987,"derivative":{"underlying":"Common Stock","underlying_shares":10987},"source":{"system":"sec-edgar","filing":"0001172252-26-000002","document":"form4-06082026_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000117225226000002/form4-06082026_040612.xml","form_type":"4"}},{"id":746628,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T16:15:16.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":42350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":42350,"derivative":{"exercise_price":4.71,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":42350},"source":{"system":"sec-edgar","filing":"0001172252-26-000002","document":"form4-06082026_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000117225226000002/form4-06082026_040612.xml","form_type":"4"}},{"id":746627,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T16:15:16.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":true,"shares":11580,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":25540,"source":{"system":"sec-edgar","filing":"0001172252-26-000002","document":"form4-06082026_040612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000117225226000002/form4-06082026_040612.xml","form_type":"4"}},{"id":791239,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":49612,"kind":"person","name":"Hall Jesse Wayne","position":1,"cik":"0002065269","reported_name":"Hall Jesse Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2026-05-05T20:15:15.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":36375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of May 1, 2025, subject to the Continuous Service (as defined in the Issuer's 2024 Inducement Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of May 1, 2025, subject to the Continuous Service (as defined in the Issuer's 2024 Inducement Plan) of the Reporting Person as of each such date."}],"balance_after":109125,"derivative":{"underlying":"Common Stock","underlying_shares":36375},"source":{"system":"sec-edgar","filing":"0002065269-26-000004","document":"form4-05052026_040505.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000206526926000004/form4-05052026_040505.xml","form_type":"4"}},{"id":791238,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":49612,"kind":"person","name":"Hall Jesse Wayne","position":1,"cik":"0002065269","reported_name":"Hall Jesse Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-05T20:15:15.000Z","date":"2026-05-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":9330,"price":4.41,"value":41145.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":27045,"source":{"system":"sec-edgar","filing":"0002065269-26-000004","document":"form4-05052026_040505.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000206526926000004/form4-05052026_040505.xml","form_type":"4"}},{"id":791237,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":49612,"kind":"person","name":"Hall Jesse Wayne","position":1,"cik":"0002065269","reported_name":"Hall Jesse Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-05T20:15:15.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":true,"shares":36375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":36375,"source":{"system":"sec-edgar","filing":"0002065269-26-000004","document":"form4-05052026_040505.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000206526926000004/form4-05052026_040505.xml","form_type":"4"}},{"id":799968,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-04-27T23:27:01.000Z","date":"2026-04-23","kind":"sale","planned":false,"acquired":false,"shares":300000,"price":4.53,"value":1359000.0,"ownership":{"direct":false,"nature":"Holdings of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":13950000,"source":{"system":"sec-edgar","filing":"0001373604-26-000034","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360426000034/form4.xml","form_type":"4"}},{"id":865345,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-03T21:10:13.000Z","date":"2026-03-01","kind":"exercise","planned":false,"acquired":false,"shares":2375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2375},"source":{"system":"sec-edgar","filing":"0001957554-26-000011","document":"form4-03032026_040301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000011/form4-03032026_040301.xml","form_type":"4"}},{"id":865344,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:10:13.000Z","date":"2026-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":677,"price":2.87,"value":1942.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":187453,"source":{"system":"sec-edgar","filing":"0001957554-26-000011","document":"form4-03032026_040301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000011/form4-03032026_040301.xml","form_type":"4"}},{"id":865343,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:10:13.000Z","date":"2026-03-01","kind":"exercise","planned":false,"acquired":true,"shares":2375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":188130,"source":{"system":"sec-edgar","filing":"0001957554-26-000011","document":"form4-03032026_040301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000011/form4-03032026_040301.xml","form_type":"4"}},{"id":915786,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-06T23:10:28.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":961700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":961700,"derivative":{"exercise_price":3.61,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":961700},"source":{"system":"sec-edgar","filing":"0001604457-26-000007","document":"form4-02062026_110224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000160445726000007/form4-02062026_110224.xml","form_type":"4"}},{"id":915785,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2026-02-06T23:10:28.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":274800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":274800,"derivative":{"underlying":"Common Stock","underlying_shares":274800},"source":{"system":"sec-edgar","filing":"0001604457-26-000007","document":"form4-02062026_110224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000160445726000007/form4-02062026_110224.xml","form_type":"4"}},{"id":915784,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":26569,"kind":"person","name":"Kolbeck Roland Wilhelm","position":1,"cik":"0002076327","reported_name":"Kolbeck Roland Wilhelm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-06T23:06:23.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":334900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":334900,"derivative":{"exercise_price":3.61,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":334900},"source":{"system":"sec-edgar","filing":"0002076327-26-000002","document":"form4-02062026_110219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000207632726000002/form4-02062026_110219.xml","form_type":"4"}},{"id":915783,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":26569,"kind":"person","name":"Kolbeck Roland Wilhelm","position":1,"cik":"0002076327","reported_name":"Kolbeck Roland Wilhelm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-06T23:06:23.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":95700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":95700,"derivative":{"underlying":"Common Stock","underlying_shares":95700},"source":{"system":"sec-edgar","filing":"0002076327-26-000002","document":"form4-02062026_110219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000207632726000002/form4-02062026_110219.xml","form_type":"4"}},{"id":915780,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":49612,"kind":"person","name":"Hall Jesse Wayne","position":1,"cik":"0002065269","reported_name":"Hall Jesse Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-06T23:04:49.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":343300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":343300,"derivative":{"exercise_price":3.61,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":343300},"source":{"system":"sec-edgar","filing":"0002065269-26-000002","document":"form4-02062026_110246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000206526926000002/form4-02062026_110246.xml","form_type":"4"}},{"id":915779,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":49612,"kind":"person","name":"Hall Jesse Wayne","position":1,"cik":"0002065269","reported_name":"Hall Jesse Wayne","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-06T23:04:49.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":98100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":98100,"derivative":{"underlying":"Common Stock","underlying_shares":98100},"source":{"system":"sec-edgar","filing":"0002065269-26-000002","document":"form4-02062026_110246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000206526926000002/form4-02062026_110246.xml","form_type":"4"}},{"id":915782,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-06T23:00:49.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":346800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":346800,"derivative":{"exercise_price":3.61,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":346800},"source":{"system":"sec-edgar","filing":"0001957554-26-000009","document":"form4-02062026_110245.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000009/form4-02062026_110245.xml","form_type":"4"}},{"id":915781,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-06T23:00:49.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":99100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":99100,"derivative":{"underlying":"Common Stock","underlying_shares":99100},"source":{"system":"sec-edgar","filing":"0001957554-26-000009","document":"form4-02062026_110245.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000009/form4-02062026_110245.xml","form_type":"4"}},{"id":916257,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67432,"kind":"person","name":"Davis Hugh M.","position":1,"cik":"0002045027","reported_name":"Davis Hugh M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-06T18:08:08.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":336300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":336300,"derivative":{"exercise_price":3.61,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":336300},"source":{"system":"sec-edgar","filing":"0002045027-26-000004","document":"form4-02062026_110205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2045027/000204502726000004/form4-02062026_110205.xml","form_type":"4"}},{"id":916256,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67432,"kind":"person","name":"Davis Hugh M.","position":1,"cik":"0002045027","reported_name":"Davis Hugh M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Restricted Stock Units","published_at":"2026-02-06T18:08:08.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":96100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":96100,"derivative":{"underlying":"Common Stock","underlying_shares":96100},"source":{"system":"sec-edgar","filing":"0002045027-26-000004","document":"form4-02062026_110205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2045027/000204502726000004/form4-02062026_110205.xml","form_type":"4"}},{"id":916083,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-06T18:02:58.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":341900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":341900,"derivative":{"exercise_price":3.61,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":341900},"source":{"system":"sec-edgar","filing":"0001781549-26-000013","document":"form4-02062026_110255.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000013/form4-02062026_110255.xml","form_type":"4"}},{"id":916082,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-06T18:02:58.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":97700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":97700,"derivative":{"underlying":"Common Stock","underlying_shares":97700},"source":{"system":"sec-edgar","filing":"0001781549-26-000013","document":"form4-02062026_110255.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000013/form4-02062026_110255.xml","form_type":"4"}},{"id":917412,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2026-02-05T21:45:57.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":false,"shares":63475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":190425,"derivative":{"underlying":"Common Stock","underlying_shares":63475},"source":{"system":"sec-edgar","filing":"0001604457-26-000005","document":"form4-02052026_090254.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000160445726000005/form4-02052026_090254.xml","form_type":"4"}},{"id":917411,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-02-05T21:45:57.000Z","date":"2026-02-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":18611,"price":3.47,"value":64580.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1543886,"source":{"system":"sec-edgar","filing":"0001604457-26-000005","document":"form4-02052026_090254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000160445726000005/form4-02052026_090254.xml","form_type":"4"}},{"id":917410,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-02-05T21:45:57.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":true,"shares":63475,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":1562497,"source":{"system":"sec-edgar","filing":"0001604457-26-000005","document":"form4-02052026_090254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000160445726000005/form4-02052026_090254.xml","form_type":"4"}},{"id":917409,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-05T21:41:46.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":false,"shares":22025,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":66075,"derivative":{"underlying":"Common Stock","underlying_shares":22025},"source":{"system":"sec-edgar","filing":"0001957554-26-000007","document":"form4-02052026_090243.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000007/form4-02052026_090243.xml","form_type":"4"}},{"id":917408,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-05T21:41:46.000Z","date":"2026-02-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":6449,"price":3.47,"value":22378.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":185755,"source":{"system":"sec-edgar","filing":"0001957554-26-000007","document":"form4-02052026_090243.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000007/form4-02052026_090243.xml","form_type":"4"}},{"id":917407,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-05T21:41:46.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":true,"shares":22025,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":192204,"source":{"system":"sec-edgar","filing":"0001957554-26-000007","document":"form4-02052026_090243.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000007/form4-02052026_090243.xml","form_type":"4"}},{"id":917778,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-05T16:48:42.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":false,"shares":20875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":62625,"derivative":{"underlying":"Common Stock","underlying_shares":20875},"source":{"system":"sec-edgar","filing":"0001781549-26-000011","document":"form4-02052026_090237.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000011/form4-02052026_090237.xml","form_type":"4"}},{"id":917777,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-05T16:48:42.000Z","date":"2026-02-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":5937,"price":3.47,"value":20601.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":192260,"source":{"system":"sec-edgar","filing":"0001781549-26-000011","document":"form4-02052026_090237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000011/form4-02052026_090237.xml","form_type":"4"}},{"id":917776,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-05T16:48:42.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":true,"shares":20875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":198197,"source":{"system":"sec-edgar","filing":"0001781549-26-000011","document":"form4-02052026_090237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000011/form4-02052026_090237.xml","form_type":"4"}},{"id":918004,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67432,"kind":"person","name":"Davis Hugh M.","position":1,"cik":"0002045027","reported_name":"Davis Hugh M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Restricted Stock Units","published_at":"2026-02-05T16:44:00.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":false,"shares":18675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":56025,"derivative":{"underlying":"Common Stock","underlying_shares":18675},"source":{"system":"sec-edgar","filing":"0002045027-26-000002","document":"form4-02052026_090256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2045027/000204502726000002/form4-02052026_090256.xml","form_type":"4"}},{"id":918003,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67432,"kind":"person","name":"Davis Hugh M.","position":1,"cik":"0002045027","reported_name":"Davis Hugh M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2026-02-05T16:44:00.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":true,"shares":18675,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":45425,"source":{"system":"sec-edgar","filing":"0002045027-26-000002","document":"form4-02052026_090256.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2045027/000204502726000002/form4-02052026_090256.xml","form_type":"4"}},{"id":917775,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-05T16:38:04.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":29500,"derivative":{"underlying":"Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001781549-26-000009","document":"form4a-02052026_090200.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000009/form4a-02052026_090200.xml","form_type":"4/A","original_submission_date":"2026-02-03"}},{"id":917774,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Resticted Stock Units","published_at":"2026-02-05T16:38:04.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":7500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001781549-26-000009","document":"form4a-02052026_090200.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000009/form4a-02052026_090200.xml","form_type":"4/A","original_submission_date":"2026-02-03"}},{"id":917773,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-05T16:38:04.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001781549-26-000009","document":"form4a-02052026_090200.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000009/form4a-02052026_090200.xml","form_type":"4/A","original_submission_date":"2026-02-03"}},{"id":917772,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-05T16:38:04.000Z","date":"2026-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":10686,"price":3.51,"value":37507.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":177322,"source":{"system":"sec-edgar","filing":"0001781549-26-000009","document":"form4a-02052026_090200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000009/form4a-02052026_090200.xml","form_type":"4/A","original_submission_date":"2026-02-03"}},{"id":917771,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-05T16:38:04.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":true,"shares":14750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":188008,"source":{"system":"sec-edgar","filing":"0001781549-26-000009","document":"form4a-02052026_090200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000009/form4a-02052026_090200.xml","form_type":"4/A","original_submission_date":"2026-02-03"}},{"id":917770,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-05T16:38:04.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":173258,"source":{"system":"sec-edgar","filing":"0001781549-26-000009","document":"form4a-02052026_090200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000009/form4a-02052026_090200.xml","form_type":"4/A","original_submission_date":"2026-02-03"}},{"id":917769,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-05T16:38:04.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":true,"shares":11250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":165758,"source":{"system":"sec-edgar","filing":"0001781549-26-000009","document":"form4a-02052026_090200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000009/form4a-02052026_090200.xml","form_type":"4/A","original_submission_date":"2026-02-03"}},{"id":921140,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T22:36:49.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":29500,"derivative":{"underlying":"Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001957554-26-000005","document":"form4-02032026_100245.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000005/form4-02032026_100245.xml","form_type":"4"}},{"id":921139,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-03T22:36:49.000Z","date":"2026-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":4984,"price":3.51,"value":17493.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":170179,"source":{"system":"sec-edgar","filing":"0001957554-26-000005","document":"form4-02032026_100245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000005/form4-02032026_100245.xml","form_type":"4"}},{"id":921138,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-03T22:36:49.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":true,"shares":14750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":175163,"source":{"system":"sec-edgar","filing":"0001957554-26-000005","document":"form4-02032026_100245.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000005/form4-02032026_100245.xml","form_type":"4"}},{"id":922012,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-03T17:34:33.000Z","date":"2025-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":15980,"price":2.48,"value":39630.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This amendment is being filed to correct the number of shares that were withheld by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units previously reported.  This adjustment will affect the amount of securities beneficially owned following the reported transaction in subsequent filings."}],"balance_after":102773,"source":{"system":"sec-edgar","filing":"0001781549-26-000007","document":"form4-02032026_100229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000007/form4-02032026_100229.xml","form_type":"4"}},{"id":922011,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-03T17:32:06.000Z","date":"2025-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":15980,"price":2.48,"value":39630.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This amendment is being filed to correct the number of shares that were withheld by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units previously reported.  This adjustment will affect the amount of securities beneficially owned following the reported transaction in subsequent filings."}],"balance_after":102773,"source":{"system":"sec-edgar","filing":"0001781549-26-000005","document":"form4a-02032026_100202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000005/form4a-02032026_100202.xml","form_type":"4/A","original_submission_date":"2025-02-04"}},{"id":950265,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T21:32:24.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":false,"shares":29150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units  vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units  vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":30034,"derivative":{"underlying":"Common Stock","underlying_shares":29150},"source":{"system":"sec-edgar","filing":"0001604457-26-000003","document":"form4-01052026_090114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000160445726000003/form4-01052026_090114.xml","form_type":"4"}},{"id":950264,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-01-05T21:32:24.000Z","date":"2026-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":9952,"price":2.88,"value":28661.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":1499022,"source":{"system":"sec-edgar","filing":"0001604457-26-000003","document":"form4-01052026_090114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000160445726000003/form4-01052026_090114.xml","form_type":"4"}},{"id":950263,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-01-05T21:32:24.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":true,"shares":29150,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":1508974,"source":{"system":"sec-edgar","filing":"0001604457-26-000003","document":"form4-01052026_090114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000160445726000003/form4-01052026_090114.xml","form_type":"4"}},{"id":950262,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T21:27:39.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":false,"shares":13200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":13600,"derivative":{"underlying":"Common Stock","underlying_shares":13200},"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":950261,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T21:27:39.000Z","date":"2026-01-01","kind":"exercise","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date."}],"balance_after":7500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":950260,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T21:27:39.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":73750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"50% of the shares underlying these restricted stock units vested on each of December 31, 2024 and December 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"50% of the shares underlying these restricted stock units vested on each of December 31, 2024 and December 31, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":73750},"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":950259,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:27:39.000Z","date":"2026-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":4461,"price":2.88,"value":12847.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":160413,"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":950258,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:27:39.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":true,"shares":13200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":164874,"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":950257,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:27:39.000Z","date":"2026-01-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2250,"price":3.01,"value":6772.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":151674,"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":950256,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:27:39.000Z","date":"2026-01-01","kind":"exercise","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":153924,"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":950255,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:27:39.000Z","date":"2025-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":19934,"price":3.01,"value":60001.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":146424,"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":950254,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":63153,"kind":"person","name":"Balthaser Kevin","position":1,"cik":"0001957554","reported_name":"Balthaser Kevin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:27:39.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":73750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":166358,"source":{"system":"sec-edgar","filing":"0001957554-26-000003","document":"form4-01052026_090132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000195755426000003/form4-01052026_090132.xml","form_type":"4"}},{"id":951729,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T16:30:13.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":false,"shares":18150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":18700,"derivative":{"underlying":"Common Stock","underlying_shares":18150},"source":{"system":"sec-edgar","filing":"0001781549-26-000003","document":"form4-01052026_090101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000003/form4-01052026_090101.xml","form_type":"4"}},{"id":951728,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T16:30:13.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":73750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"50% of the shares underlying these restricted stock units vested on each of December 31, 2024 and December 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"50% of the shares underlying these restricted stock units vested on each of December 31, 2024 and December 31, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":73750},"source":{"system":"sec-edgar","filing":"0001781549-26-000003","document":"form4-01052026_090101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000003/form4-01052026_090101.xml","form_type":"4"}},{"id":951727,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-01-05T16:30:13.000Z","date":"2026-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":6171,"price":2.88,"value":17772.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":155041,"source":{"system":"sec-edgar","filing":"0001781549-26-000003","document":"form4-01052026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000003/form4-01052026_090101.xml","form_type":"4"}},{"id":951726,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-01-05T16:30:13.000Z","date":"2026-01-02","kind":"exercise","planned":false,"acquired":true,"shares":18150,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":161212,"source":{"system":"sec-edgar","filing":"0001781549-26-000003","document":"form4-01052026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000003/form4-01052026_090101.xml","form_type":"4"}},{"id":951725,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-01-05T16:30:13.000Z","date":"2025-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":33994,"price":3.01,"value":102321.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4."}],"balance_after":143062,"source":{"system":"sec-edgar","filing":"0001781549-26-000003","document":"form4-01052026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000003/form4-01052026_090101.xml","form_type":"4"}},{"id":951724,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67414,"kind":"person","name":"Loerop James","position":1,"cik":"0001781549","reported_name":"Loerop James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-01-05T16:30:13.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":73750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":177056,"source":{"system":"sec-edgar","filing":"0001781549-26-000003","document":"form4-01052026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781549/000178154926000003/form4-01052026_090101.xml","form_type":"4"}},{"id":980513,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67432,"kind":"person","name":"Davis Hugh M.","position":1,"cik":"0002045027","reported_name":"Davis Hugh M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Restricted Stock Units","published_at":"2025-12-04T16:50:45.000Z","date":"2025-12-02","kind":"exercise","planned":false,"acquired":false,"shares":26750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to the Continuous Service (as defined in the Issuer's 2024 Inducement Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to the Continuous Service (as defined in the Issuer's 2024 Inducement Plan) of the Reporting Person as of each such date."}],"balance_after":80250,"derivative":{"underlying":"Common Stock","underlying_shares":26750},"source":{"system":"sec-edgar","filing":"0002045027-25-000003","document":"form4-12042025_091242.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2045027/000204502725000003/form4-12042025_091242.xml","form_type":"4"}},{"id":980512,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67432,"kind":"person","name":"Davis Hugh M.","position":1,"cik":"0002045027","reported_name":"Davis Hugh M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2025-12-04T16:50:45.000Z","date":"2025-12-02","kind":"exercise","planned":false,"acquired":true,"shares":26750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":26750,"source":{"system":"sec-edgar","filing":"0002045027-25-000003","document":"form4-12042025_091242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2045027/000204502725000003/form4-12042025_091242.xml","form_type":"4"}},{"id":1074104,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":26569,"kind":"person","name":"Kolbeck Roland Wilhelm","position":1,"cik":"0002076327","reported_name":"Kolbeck Roland Wilhelm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-08-05T20:33:44.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":510000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":510000,"derivative":{"exercise_price":1.53,"expiration_date":"2035-07-31","underlying":"Common Stock","underlying_shares":510000},"source":{"system":"sec-edgar","filing":"0001415889-25-021045","document":"form4-08052025_080841.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925021045/form4-08052025_080841.xml","form_type":"4"}},{"id":1074103,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":26569,"kind":"person","name":"Kolbeck Roland Wilhelm","position":1,"cik":"0002076327","reported_name":"Kolbeck Roland Wilhelm","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-08-05T20:33:44.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":145500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":145500,"derivative":{"underlying":"Common Stock","underlying_shares":145500},"source":{"system":"sec-edgar","filing":"0001415889-25-021045","document":"form4-08052025_080841.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925021045/form4-08052025_080841.xml","form_type":"4"}},{"id":1117609,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":391,"kind":"person","name":"MILANO VINCENT","position":1,"cik":"0001187159","reported_name":"MILANO VINCENT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-09T20:20:29.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":false,"shares":4793,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 6, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 6, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4793},"source":{"system":"sec-edgar","filing":"0001415889-25-016251","document":"form4-06092025_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1187159/000141588925016251/form4-06092025_040610.xml","form_type":"4"}},{"id":1117608,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":391,"kind":"person","name":"MILANO VINCENT","position":1,"cik":"0001187159","reported_name":"MILANO VINCENT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-09T20:20:29.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":11580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":11580,"derivative":{"underlying":"Common Stock","underlying_shares":11580},"source":{"system":"sec-edgar","filing":"0001415889-25-016251","document":"form4-06092025_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1187159/000141588925016251/form4-06092025_040610.xml","form_type":"4"}},{"id":1117607,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":391,"kind":"person","name":"MILANO VINCENT","position":1,"cik":"0001187159","reported_name":"MILANO VINCENT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:20:29.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":42350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 5, 2025, subject to the Reporting Person's Continuous Service (as defined in the Plan) through each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":42350,"derivative":{"exercise_price":1.56,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":42350},"source":{"system":"sec-edgar","filing":"0001415889-25-016251","document":"form4-06092025_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1187159/000141588925016251/form4-06092025_040610.xml","form_type":"4"}},{"id":1117606,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":391,"kind":"person","name":"MILANO VINCENT","position":1,"cik":"0001187159","reported_name":"MILANO VINCENT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:20:29.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":true,"shares":4793,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":17316,"source":{"system":"sec-edgar","filing":"0001415889-25-016251","document":"form4-06092025_040610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187159/000141588925016251/form4-06092025_040610.xml","form_type":"4"}},{"id":1117452,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-09T20:20:24.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":false,"shares":4793,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 6, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 6, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4793},"source":{"system":"sec-edgar","filing":"0001415889-25-016250","document":"form4-06092025_040608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925016250/form4-06092025_040608.xml","form_type":"4"}},{"id":1117451,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-09T20:20:24.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":11580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":11580,"derivative":{"underlying":"Common Stock","underlying_shares":11580},"source":{"system":"sec-edgar","filing":"0001415889-25-016250","document":"form4-06092025_040608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925016250/form4-06092025_040608.xml","form_type":"4"}},{"id":1117450,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:20:24.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":42350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 5, 2025, subject to the Reporting Person's Continuous Service (as defined in the Plan) through each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":42350,"derivative":{"exercise_price":1.56,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":42350},"source":{"system":"sec-edgar","filing":"0001415889-25-016250","document":"form4-06092025_040608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925016250/form4-06092025_040608.xml","form_type":"4"}},{"id":1117449,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40389,"kind":"person","name":"Mehra Anand","position":1,"cik":"0001590102","reported_name":"Mehra Anand","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:20:24.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":true,"shares":4793,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":714823,"source":{"system":"sec-edgar","filing":"0001415889-25-016250","document":"form4-06092025_040608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925016250/form4-06092025_040608.xml","form_type":"4"}},{"id":1117883,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40485,"kind":"person","name":"Humphries William D.","position":1,"cik":"0001674278","reported_name":"Humphries William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-09T20:20:18.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":false,"shares":4793,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 6, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 6, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4793},"source":{"system":"sec-edgar","filing":"0001415889-25-016249","document":"form4-06092025_040606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674278/000141588925016249/form4-06092025_040606.xml","form_type":"4"}}],"next_cursor":"2025-06-09T20:20:18.000000Z,1117883"}